慢性脫髓鞘多發性神經炎(CIDP) 市場規模、佔有率和成長分析：按療法、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033 年產業預測

2024 年全球慢性脫髓鞘多發性神經炎(CIDP) 市場價值為 17.2 億美元，預計從 2025 年的 18.5 億美元成長到 2033 年的 32.8 億美元，預測期 (2026-2033 年) 的複合年成長率為 7.4%。

慢性脫髓鞘多發性神經炎(CIDP) 的全球市場涵蓋了診斷、生物製藥和支持療法，用於治療這種罕見的自體免疫神經病變，該疾病會嚴重影響患者的運動和感覺功能。 CIDP 會顯著降低患者的生活品質，且長期靜脈注射免疫球蛋白 (IVIG) 治療費用高昂，因此，人們越來越需要經濟有效的替代療法。皮下注射免疫球蛋白 (SCIG) 和 Fc 修飾的單株抗體的引入，透過減少輸注頻率來提高患者依從性，從而推動了市場成長。 SCIG 能夠降低醫療成本和再入院率的證據，促使保險公司擴大了報銷範圍。隨著生技公司投資開發創新療法，新的機會正在湧現，尤其是在那些存在巨大未滿足需求的低度開發市場。

全球慢性脫髓鞘多發性神經炎（CIDP）市場成長要素

醫療專業人員對慢性脫髓鞘多發性神經炎(CIDP) 的認知不斷提高，顯著促進了診斷和轉診流程的改進，從而擴大了新療法的潛在患者群體。隨著臨床醫生越來越擅長識別特徵性症狀，他們越來越傾向於考慮緩解疾病療法，這導致處方率上升，創新療法的接受度也更高。這種認知的提高促進了跨學科合作，簡化了診療流程，並增加了對先進治療方案的需求。快速介入不僅使患者受益，也驗證了新產品的臨床療效，從而刺激了對研發的進一步投入。

全球慢性脫髓鞘多發性神經炎（CIDP）市場限制因素

慢性脫髓鞘多發性神經炎(CIDP) 缺乏全球公認的生物標記物，這給早期準確診斷帶來了巨大挑戰，可能導致診斷延遲和誤診。可靠診斷標記物的匱乏迫使醫療專業人員頻繁依賴排除性診斷和主觀臨床評估，從而可能延遲適當治療的啟動。這種診斷的不確定性也可能使臨床醫生在確診前不願採用創新且可能昂貴的療法。因此，這些因素顯著限制了市場擴張，並阻礙了 CIDP 領域新療法的及時推出。

慢性脫髓鞘多發性神經炎（CIDP）市場的全球趨勢

慢性脫髓鞘多發性神經炎(CIDP) 的全球市場正經歷顯著的變革，這主要得益於創新生物製藥的進步。生技公司正致力於研發標靶免疫機制的新一代療法，特別是透過開發抗體和重組蛋白。提高選擇性、減少給藥頻率和增強患者遵守用藥是治療方案變革的關鍵。專業製藥公司與學術研究機構之間的合作正在加強轉化研究，而監管機構也越來越接受新的臨床終點指標。這種不斷變化的格局使生物製藥成為傳統療法的理想替代方案，並有可能重新定義全球長期管理策略。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球慢性脫髓鞘多發性神經炎(CIDP) 市場規模：依治療類型分類

• 皮質類固醇
• 靜脈注射免疫球蛋白（IVIg）
• 皮下注射免疫球蛋白（SCIg）
• 血漿置換（血漿分離術）
• 免疫抑制劑和免疫調節劑
• 其他

全球慢性脫髓鞘多發性神經炎（CIDP）市場規模：依給藥途徑分類

• 靜脈
• 皮下
• 口服

全球慢性脫髓鞘多發性神經炎(CIDP) 市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房
• 網路藥房

全球慢性脫髓鞘多發性神經炎(CIDP) 市場規模：依最終用戶分類

• 醫院
• 神經科診所
• 門診靜脈輸液治療中心
• 家庭醫療保健環境

全球慢性脫髓鞘多發性神經炎(CIDP) 市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• CSL Behring LLC
• Grifols SA
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion Biopharma
• Biotest AG
• LFB USA Inc
• Sanofi SA
• Argenx SE
• Johnson & Johnson Services Inc
• Pfizer Inc
• Novartis AG
• AstraZeneca plc
• GlaxoSmithKline plc
• Merck & Co Inc
• Bristol Myers Squibb Company
• Teva Pharmaceutical Industries Ltd
• Viatris Inc
• Sandoz International GmbH
• Lupin Limited

結論與建議

Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market size was valued at USD 1.72 Billion in 2024 and is poised to grow from USD 1.85 Billion in 2025 to USD 3.28 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).

The global market for chronic inflammatory demyelinating polyneuropathy (CIDP) encompasses diagnostics, biologics, and supportive therapies for a rare autoimmune neuropathy that severely affects motor and sensory functions. The disease not only significantly diminishes patient quality of life but also involves the high expenses associated with long-term intravenous immunoglobulin (IVIG) treatments, spurring the need for cost-effective alternatives. The introduction of subcutaneous immunoglobulin (SCIG) and Fc-engineered monoclonal antibodies is driving market growth by promoting patient adherence through fewer required infusions. Evidence shows that SCIG leads to reduced healthcare costs and lower hospital readmission rates, encouraging insurers to enhance reimbursement. As biotech firms invest in the development of innovative therapies, new opportunities are emerging, particularly in developing markets with considerable unmet needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market Segments Analysis

Global chronic inflammatory demyelinating polyneuropathy CIDP market is segmented by treatment type, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into corticosteroids, intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), plasma exchange (Plasmapheresis), immunosuppressants & immunomodulators and others. Based on route of administration, the market is segmented into intravenous, subcutaneous and oral. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, specialty pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, neurology clinics, ambulatory infusion centers and home healthcare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market

The rising awareness of chronic inflammatory demyelinating polyneuropathy (CIDP) among healthcare professionals has significantly contributed to improved detection and referral processes, thereby expanding the potential patient demographic for novel therapies. As clinicians become more attuned to characteristic symptomatology, they are increasingly inclined to explore disease-modifying treatments, resulting in elevated prescription rates and wider acceptance of innovative treatment methods. This enhanced awareness fosters interdisciplinary collaboration, streamlining care processes and increasing the demand for advanced therapeutic options. Prompt intervention not only benefits patients but also underscores the clinical efficacy of new products, thereby encouraging further investment in research and development.

Restraints in the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market

The absence of universally recognized biomarkers for chronic inflammatory demyelinating polyneuropathy (CIDP) poses significant challenges in achieving early and accurate diagnoses, resulting in delays and potential misclassifications. As reliable laboratory markers are scarce, healthcare professionals often rely on exclusionary methods and subjective clinical evaluations, which can postpone the initiation of suitable treatments. This diagnostic uncertainty may cause clinicians to be cautious about prescribing innovative and potentially expensive therapies until a clearer diagnosis is confirmed. Consequently, these factors considerably restrict market expansion and hinder the timely adoption of new treatment alternatives in the CIDP arena.

Market Trends of the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market

The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is experiencing a notable shift driven by the advancement of innovative biologics. Biotech companies are intensifying their focus on next-generation therapies, particularly targeting immune mechanisms through antibody and recombinant protein development. The emphasis on selectivity, reduced infusion frequency, and improved patient adherence marks a transformative approach in treatment options. Collaborations between specialty pharmaceutical firms and academic research centers enhance translational efforts, while regulatory bodies exhibit increasing receptiveness to novel clinical endpoints. This evolving landscape is positioning biologics as a compelling alternative to traditional therapies, potentially redefining long-term management strategies worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Intravenous Immunoglobulin (IVIg)
• Subcutaneous Immunoglobulin (SCIg)
• Plasma Exchange (Plasmapheresis)
• Immunosuppressants & Immunomodulators
• Others

Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous
• Oral

Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Neurology Clinics
• Ambulatory Infusion Centers
• Home Healthcare Settings

Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size & CAGR (2026-2033)

• North America (Treatment Type, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB USA Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Argenx SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations